Personal care composition

Abstract

A personal care composition is disclosed comprising a moringa oil and a coconut oil, wherein the weight ratio of the moringa oil to the coconut oil is at least 1.4:1.

Description

Technical Field

[0001] This invention relates to personal care compositions comprising moringa oil and coconut oil in specific weight ratios. Surprisingly, the expression of the heme oxygenase 1 (HMOX1) gene was found to be synergistically upregulated within this ratio. Background Technology

[0002] Human skin provides physicochemical protection against environmental aggressors through its barrier function, mechanical strength, and water impermeability. It is frequently exposed to harmful environments and extreme conditions, such as ultraviolet radiation, blue light, and pollution. These harmful environmental conditions can lead to the excessive production of reactive oxygen species (ROS), resulting in oxidative stress. Oxidative stress can affect our skin in a variety of ways, including signs of premature aging such as wrinkles, fine lines, and uneven skin tone.

[0003] It is known that heme oxygenase 1 (from HMOX1 The gene encodes an enzyme that exhibits protective effects against oxidative stress. It is an enzyme that catalyzes the degradation of heme into biliverdin (a precursor to bilirubin, a potent antioxidant metabolite), which possesses antioxidant and anti-inflammatory properties. Heme oxygenase 1, primarily involved in the catabolism of heme, is a crucial cytoprotective enzyme with antioxidant, anti-inflammatory, and anti-apoptotic properties.

[0004] Stimulate HMOX1 The genes then stimulate the degradation of heme, thereby providing anti-aging, antioxidant, and anti-inflammatory benefits. Human skin is also a frequent site of inflammation, oxidative stress, and cell damage.

[0005] Therefore, the inventors have recognized the need to develop a method that can improve HMOX1 A personal care composition expressing gene expression was developed, and a personal care composition containing moringa oil and coconut oil was developed. Surprisingly, it was found that when the weight ratio of moringa oil to coconut oil was at least 1.4:1, HMOX1 Gene expression can be significantly upregulated. Summary of the Invention

[0006] In a first aspect, the present invention relates to a personal care composition comprising moringa oil and coconut oil, wherein the weight ratio of moringa oil to coconut oil is at least 1.4:1.

[0007] In a second aspect, the present invention relates to a method for providing antioxidant, anti-inflammatory, anti-apoptotic and / or anti-aging benefits; reducing oxidative stress; and / or upregulating the expression of the heme oxygenase 1 gene, comprising the step of topically applying the composition of the invention to the skin.

[0008] In a third aspect, the present invention relates to the use of the compositions of the invention for providing antioxidant, anti-inflammatory, and anti-apoptotic benefits; reducing oxidative stress; and / or upregulating the expression of the heme oxygenase 1 gene.

[0009] All other aspects of the invention will become more apparent upon consideration of the following detailed description and embodiments. Detailed Implementation

[0010] Except as explicitly stated in the examples, or where otherwise clearly stated, all figures indicating the amount of material or reaction conditions, physical properties of the material and / or uses in this specification may optionally be understood to be modified by the word “about”.

[0011] Unless otherwise stated, all quantities are by weight of the composition.

[0012] It should be noted that when specifying any range of values, any particular upper limit value can be associated with any particular lower limit value.

[0013] To avoid ambiguity, the word "contains" is intended to mean "including," but not necessarily "composed of" or "consisting of." In other words, the steps or options listed do not need to be exhaustive.

[0014] The disclosure of the invention found herein should be regarded as covering all embodiments found in the mutually dependent claims, regardless of the fact that the claims may be found without multiple dependencies or redundancy.

[0015] If a feature is disclosed with respect to a specific aspect of the invention (e.g., the composition of the invention), such disclosure is also considered applicable to any other aspect of the invention (e.g., the method of the invention) with the necessary modifications.

[0016] Moringa oil typically contains or is derived from moringa seed oil. Preferably, the moringa oil is derived from moringa (…). Moringa oleifera ), winged moringa ( Moringa pterygosperma ), Moringa arabic Moringa peregrina ), Pakistan Moringa ( Moringa concanensis ) or elephant leg tree ( Moringa drouhardii Seeds of at least one of the following genera: Moringa. Moringa seeds are characterized by the presence of an oil, the content of which varies from 10% to 80%, preferably 20% to 60%, depending on the species and seed maturity. For Moringa species, the oil content in Moringa seeds ranges from 15% to 45%, preferably 21% to 34%. For clarity, Moringa oil is typically liquid at 25°C and atmospheric pressure.

[0017] Preferably, moringa oil is extracted from moringa seeds. Preferably, moringa oil is extracted by cold pressing. Preferably, moringa oil contains C 18-24 Fatty acids, more preferably, moringa oil contains C18-22 Fatty acids, and even more preferably, moringa oil contains behenic acid.

[0018] Preferably, the amount of moringa oil is 0.0001-10% by weight of the composition, more preferably 0.005-5% by weight, even more preferably 0.015-2% by weight, even more preferably 0.03-0.6% by weight, and most preferably 0.06-0.3% by weight.

[0019] Preferably, the amount of moringa seed oil is 0.0001-10% by weight of the composition, more preferably 0.005-5% by weight, even more preferably 0.015-2% by weight, even more preferably 0.03-0.6% by weight, and most preferably 0.06-0.3% by weight.

[0020] Coconut oil is an edible extract obtained from the kernel or flesh of a mature coconut harvested from a coconut tree. Preferably, coconut oil contains up to 85% saturated fatty acids by weight of the coconut oil. The saturated fatty acids may contain up to 48% lauric acid by weight of the coconut oil.

[0021] Coconut oil can be produced using either dry or wet processes. Preferably, coconut oil is produced by cold pressing. Coconut oil can be refined, hydrogenated, and / or fractionated.

[0022] In some embodiments, the coconut oil is unrefined coconut oil. Preferably, the coconut oil has not been refined, bleached, and / or deodorized. Furthermore, the unrefined coconut oil has not been hydrogenated or fractionated.

[0023] Preferably, the weight ratio of moringa oil to coconut oil is in the range of 1.4:1 to 200:1, more preferably 1.4:1 to 50:1, even more preferably 1.4:1 to 20:1, and most preferably in the range of 1.4:1 to 15:1. In some embodiments, the weight ratio of moringa oil to coconut oil is preferably in the range of 2.8:1 to 200:1, more preferably 2.8:1 to 50:1, and even more preferably in the range of 2.8:1 to 15:1. In a particularly preferred embodiment, the weight ratio of moringa oil to coconut oil is preferably in the range of 2.8:1 to 8:1, more preferably in the range of 2.8:1 to 6:1.

[0024] Preferably, the weight ratio of moringa seed oil to coconut oil is in the range of 1.4:1 to 200:1, more preferably 1.4:1 to 50:1, even more preferably 1.4:1 to 20:1, and most preferably in the range of 1.4:1 to 15:1. In some embodiments, the weight ratio of moringa seed oil to coconut oil is preferably in the range of 2.8:1 to 200:1, more preferably 2.8:1 to 50:1, and even more preferably in the range of 2.8:1 to 15:1. In a particularly preferred embodiment, the weight ratio of moringa seed oil to coconut oil is preferably in the range of 2.8:1 to 8:1, more preferably in the range of 2.8:1 to 6:1.

[0025] Preferably, the amount of coconut oil present is 0.00001-10% by weight of the composition, more preferably 0.0001-5% by weight, even more preferably 0.001-2% by weight, even more preferably 0.003-0.6% by weight, and most preferably 0.01-0.2% by weight.

[0026] The composition preferably contains a cleaning surfactant. The composition may contain more than one cleaning surfactant. The cleaning surfactant may be selected from soaps, non-soap anionic, cationic, nonionic, amphoteric surfactants, and mixtures thereof. Many suitable surfactant compounds are available and are well described in the literature, such as in Schwartz, Perry, and Berch's "Surface-Active Agents and Detergents," Volumes I and II. Preferred surfactant compounds that may be used are soaps, non-soap anionic, nonionic surfactants, amphoteric surfactants, or mixtures thereof.

[0027] Suitable non-soap anionic surfactants include linear alkylbenzene sulfonates, primary and secondary alkyl sulfates, especially C8-C... 15 Primary alkyl sulfates; alkyl ether sulfates; olefin sulfonates; alkyl xylene sulfonates; dialkyl sulfosuccinates; fatty acid ester sulfonates; or mixtures thereof. Sodium salts are generally preferred.

[0028] The preferred non-soap anionic surfactants are straight-chain alkylbenzene sulfonates, especially those with alkyl chains of C8-C9. 15 The linear alkylbenzene sulfonate. Preferably, the content of the linear alkylbenzene sulfonate is 0%-30% by weight of the total composition, more preferably 1%-25% by weight, and most preferably 2%-15% by weight.

[0029] The nonionic surfactants that can be used include primary alcohol ethoxylates and secondary alcohol ethoxylates, particularly C8 to C8 ethoxylates with an average of 1 to 20 moles of ethylene oxide per mole of alcohol. 20 Aliphatic alcohols, more specifically, are C-terminated with an average of 1 to 10 moles of ethylene oxide per mole of alcohol. 10 To C 15 Primary and secondary aliphatic alcohols. Non-ethoxylated nonionic surfactants include alkyl polyglycosides, glycerol monoethers, and polyhydroxyamides (glucosamides). Preferably, the content of the nonionic surfactant is 0% to 30% by weight of the total formulation containing the microcapsules of the present invention, more preferably 1% to 25% by weight, and most preferably 2% to 15% by weight.

[0030] Suitable amphoteric surfactants are preferably betaine surfactants. Examples of suitable amphoteric surfactants include, but are not limited to, alkyl betaine, alkylamide betaine, alkyl thiobetaine, alkyl sulfonamide betaine, and alkylamide sulfonamide betaine; preferably, those having 8 to about 18 carbons in the alkyl and acyl groups. Preferably, the amount of the amphoteric surfactant is 0 to 20% by weight of the composition, more preferably 1 to 10% by weight.

[0031] It may also include certain monoalkyl cationic surfactants. Permissible cationic surfactants include those with the general formula R. 1 R 2 R 3 R 4 N + X - A quaternary ammonium salt wherein R is a long or short hydrocarbon chain, typically alkyl, hydroxyalkyl, or ethoxylated alkyl, and X is a counterion (e.g., where R...). 1 C8-C 22 Alkyl, preferably C8-C 10 Or C 12 -C 14 Alkyl, R 2 It is a methyl group, and can be the same or different R. 3 and R 4 Compounds that are methyl or hydroxyethyl; and cationic esters (e.g., choline esters).

[0032] Water-insoluble skin-beneficial agents can also be formulated into compositions as conditioning and moisturizing agents. Examples include silicone oils; hydrocarbons such as liquid paraffin, petrolatum, microcrystalline wax, and mineral oil; and vegetable triglycerides such as sunflower seed oil and cottonseed oil.

[0033] Some compositions may contain thickeners. These may be selected from, but are not limited to, cellulose products, natural gums, and acrylic polymers. Cellulose products include sodium carboxymethyl cellulose, hydroxyethyl cellulose, hydroxypropyl methyl cellulose, and combinations thereof. Suitable gums include xanthan gum, pectin, carrageenan, agar, alginate, and combinations thereof. Preferably, the composition contains an acrylic polymer, preferably homopolymers and copolymers of acrylic acid and methacrylic acid. Acrylic thickeners include homopolymers and copolymers of acrylic acid and methacrylic acid, including carbomers, such as Carbopol 1382, Carbopol 982, Ultrez, Aqua SF-1, and Aqua SF-2, available from Lubrizol Corporation. The amount of thickener may range from 0.01 to 3% by weight of the active polymer (excluding solvents or water) in the composition.

[0034] Preservatives can also be ideally incorporated into the compositions of the present invention to prevent the growth of potentially harmful microorganisms. Suitable conventional preservatives for use in the compositions of the present invention are alkyl esters of hydrobenzoic acid. Other preservatives that have recently come into use include hydantoin derivatives, propionates, and various quaternary ammonium compounds. Particularly preferred preservatives are phenoxyethanol, methylparaben, propylparaben, imidazolidinyl urea, sodium dehydroacetate, and benzyl alcohol. The preservative should be selected with consideration of the intended use of the composition and possible incompatibilities between the preservative and other components. The amount of preservative used is preferably in the range of 0.01% by weight to 2% by weight of the composition.

[0035] A variety of other optional materials may be formulated into the composition. These may include: antimicrobial agents, such as 2-hydroxy-4,2′,4′-trichlorodiphenyl ether (triclosan), 2,6-dimethyl-4-hydroxychlorobenzene, and 3,4,4′-trichlorocarbamate; exfoliating and dermal exfoliating particles, such as polyethylene and silica or alumina; cooling agents, such as menthol; skin soothing agents, such as aloe vera; and colorants.

[0036] Furthermore, the compositions of the present invention may further comprise 0.5 to 10% by weight of a chelating agent, such as tetrasodium ethylenediaminetetraacetic acid (EDTA), EHDP, or a mixture thereof; an opacifier and a pearlescent agent, such as ethylene glycol distearate, titanium dioxide, or Lytron 621 (styrene / acrylate copolymer); all of which may be used to enhance the appearance or performance of the product.

[0037] The composition may contain 10-90% by weight of water, more preferably 20-85% by weight, even more preferably 25-78% by weight, and most preferably 32-65% by weight.

[0038] Preferably, when at 20°C for about 20 seconds -1 When measured at relatively high shear rates, the composition has a viscosity in the range of at least 10 mPa s, more preferably 30 to 10,000 mPa s, even more preferably 50 to 5,000 mPa s, and most preferably 100 to 2,000 mPa s. Preferably, the composition is in liquid form at atmospheric pressure and 25°C.

[0039] Preferably, the personal care composition is a skin care composition. As used herein, the term "skin" includes the skin of the face, neck, chest, abdomen, back, arms, armpits, hands, and legs. Preferably, "skin" means the skin including the face and armpits; more preferably, skin refers to the skin on the face excluding the lips and eyelids.

[0040] Preferably, the method is non-therapeutic. Preferably, the use is non-therapeutic. The term "non-therapeutic" means used for cosmetic purposes rather than for curative or therapeutic purposes.

[0041] The present invention also provides a composition comprising moringa oil and coconut oil, wherein the weight ratio of moringa oil to coconut oil is at least 1.4:1, which provides antioxidant, anti-inflammatory, anti-apoptotic and / or anti-aging benefits; reduces oxidative stress; and / or upregulates the expression of the heme oxygenase 1 gene.

[0042] The present invention also provides the use of a combination of moringa oil and coconut oil in the preparation of a medicament for providing antioxidant, anti-inflammatory, anti-apoptotic and / or anti-aging benefits; reducing oxidative stress; and / or upregulating the expression of the heme oxygenase 1 gene, wherein the weight ratio of moringa oil to coconut oil is at least 1.4:1.

[0043] Preferably, the composition is capable of reacting heme oxygenase 1 (… HMOX1 The expression of the gene is upregulated by at least a fold change of 1.9, more preferably 1.9 to 6, even more preferably 2 to 5, even more preferably 2.7 to 4.5, and most preferably a fold change of 3.3 to 4, generally compared to personal care compositions that do not contain moringa oil or coconut oil.

[0044] The following embodiments are provided to facilitate understanding of the invention. These embodiments are not intended to limit the scope of the claims.

[0045] Example Example 1 This embodiment demonstrates the preparation of a personal care composition containing moringa seed oil and coconut oil.

[0046] Table 1

[0047] Content refers to the content of raw materials, expressed as a percentage by weight.

[0048] a: Refined Moringa seed oil, purchased from Givaudan, France.

[0049] b: Coconut oil from Cargill BV, the Netherlands.

[0050] A range of personal care compositions were prepared according to Table 1 using the following standard procedures.

[0051] Example 2 This example demonstrates the upregulation achieved through different personal care compositions. HMOX1 Performance of gene expression.

[0052] ArchSkin Living Skin Equivalent (LSE), provided by Archgene (Shanghai, China), is a 3D reconstructed human epidermal model established by culturing Chinese keratinocytes at a gas-liquid interface in a defined serum-free substrate. Squalene monohydroperoxide (SQOOH), a stress alternative, is prepared internally by subjecting squalene to solar radiation in the presence of a sensitizer.

[0053] Samples were diluted 1:1 in phosphate-buffered saline (PBS) at a volume ratio. SQOOH was diluted to 1% by weight with squalene. 10 μL of diluted SQOOH was applied topically to the LSE and left to stand for 30 seconds. The LSE was then topically treated with 10 μL of diluted sample for another 30 seconds and gently rinsed with 20 mL of PBS. After 24 hours, tissue was collected for gene expression analysis.

[0054] Extracted RNA was quantified using a Nanodrop spectrometer (Thermo Fisher Scientific, Waltham, MA, US) and reverse transcribed to generate template cDNA using Evo M-MLV RT premix for qPCR according to the manufacturer's protocol. Analysis was performed by polymerase chain reaction (PCR) using the SYBR® Green Premix Pro Taq HS qPCR kit (Accurate Biotechnology, AG11701). HMOX1 Gene expression. Selection of actin β ( ACTB The gene is used as a housekeeping gene, and all data on the relative expression of the target gene are for... ACTB Gene normalization. Fold-over-fold change in expression was calculated relative to a blank control (culture medium without active substance). All tests were performed at least three times, as shown in Table 1. HMOX1 fold change in gene expression.

[0055] The results are summarized in Table 2.

[0056] Table 2

[0057] a: Significantly superior to any one of samples A, B, or C (p<0.05) b: Significantly better than sample 3 (p<0.05) c: Significantly better than sample 1 (p<0.05) The data in Table 1 clearly show that samples 1, 2, and 3 significantly improved compared to samples A, B, or C. HMOX1 Gene expression. Sample 1 showed increased expression. HMOX1In terms of gene expression, it significantly outperformed sample 3, and sample 2 also showed improvement. HMOX1 The gene expression performance was significantly better than that of samples 1 and 3.

Claims

1. A personal care composition comprising moringa oil and coconut oil, wherein the weight ratio of moringa oil to coconut oil is at least 1.4:

1.

2. The composition according to claim 1, wherein the moringa oil comprises or is moringa seed oil.

3. The composition according to claim 2, wherein the moringa oil is extracted from the seeds of Moringa.

4. The composition according to any one of the preceding claims, wherein the moringa oil is present in an amount of 0.0001-10% by weight, more preferably 0.015-2% by weight, of the composition.

5. The composition according to any one of the preceding claims, wherein the coconut oil is unrefined coconut oil.

6. The composition according to any one of the preceding claims, wherein the coconut oil has not been hydrogenated or fractionated.

7. The composition according to any one of the preceding claims, wherein the weight ratio of the moringa oil to the coconut oil is in the range of 1.4:1 to 50:1, preferably 1.4:1 to 15:1, and more preferably 2.8:1 to 8:

1.

8. The composition according to any one of the preceding claims, wherein the weight ratio of the moringa seed oil to the coconut oil is in the range of 1.4:1 to 50:1, preferably 1.4:1 to 15:1, and more preferably 2.8:1 to 8:

1.

9. The composition according to any one of the preceding claims, wherein the coconut oil is present in an amount of 0.00001-10% by weight, preferably 0.003-0.6% by weight, of the composition.

10. The composition according to any one of the preceding claims, wherein the composition comprises 25-78% by weight of water.

11. A method for providing antioxidant, anti-inflammatory, anti-apoptotic and / or anti-aging benefits; reducing oxidative stress; and / or upregulating the expression of the heme oxygenase 1 gene, comprising the step of topically applying the composition of any one of the preceding claims to the skin.

12. Use of the composition of any one of the preceding claims for providing antioxidant, anti-inflammatory, anti-apoptotic and / or anti-aging benefits; reducing oxidative stress; and / or upregulating the expression of the heme oxygenase 1 gene.

Images